Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2027
Accreditation: 4.75 Nursing Contact Hours | 4.75 ABIM MOC II | 4.75 AMA PRA Category 1 Credit™ | 4.75 ACPE Pharmacy
Venue: Sonesta Redondo Beach & Marin, 300 North Harbor Drive, Redondo Beach, CA, 90277, United States
Official conference page for Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2027. https://binaytara.org/projects/conferences/dogmas-controversies-in-hematologic-malignancies-los-angeles-2027
About Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2027


Faculty and committee
Our Speakers
Planning Committee
Conference program and agenda
Agenda
Day 1: Friday, March 26th, 2027
All timings are in Pacific Time (PST, GMT-08:00) time.
01:30 PM - 01:50 PM
Plenary Lecture
01:50 PM - 02:00 PM
Q&A
02:00 PM - 02:15 PM
CLL - How to approach cases refractory to both a covalent BTKi and a BCL2 Inhibitor
02:15 PM - 02:30 PM
Have we solved HL? What are the unmet needs in 2025?
02:30 PM - 02:45 PM
Update in R/R MZL
02:45 PM - 03:15 PM
Case-Based Panel Discussion
03:45 PM - 04:00 PM
Induction for Acute Myeloid Leukemia: Does Anyone Still Need 7+ 3?
04:00 PM - 04:15 PM
Adding Targeted Agents to AML Therapy Backbone
04:15 PM - 04:30 PM
Chemotherapy or Chemotherapy Free: Treatment of Philadelphia Positive ALL
04:30 PM - 04:45 PM
Who Needs Transplant for ALL in CR1 : Genetics vs MRD
04:45 PM - 05:15 PM
Case-Based Panel Discussion
Day 2: Saturday, March 27th, 2027
08:15 AM - 08:30 AM
Newly Diagnosed TI - Optimal Treatment in 2026 – Which Regimen and for How Long ?
08:30 AM - 08:40 AM
Debate: Frontline TE in MM
08:40 AM - 08:50 AM
MRD stands for Make the Right Decision on Transplant
08:50 AM - 09:00 AM
MRD stands for DON’T Make the wRong Decision regarding Upfront Transplant
09:00 AM - 09:15 AM
Optimal Maintenance - Which agents for SR/HR - MRD Guided?
09:15 AM - 09:30 AM
Evaluation and Treatment of the Frail Patient
09:30 AM - 09:45 AM
Triplets and ADCs – When and How to Sequence in RRMM
09:45 AM - 09:55 AM
Case Presentation
